New device and method for treatment of heart failure patients- Step 2
|Funding from Vinnova||SEK 5 000 000|
|Project duration||November 2018 - December 2019|
|Venture||SWElife Steg 2|
Purpose and goal
The project aims to increase survival and quality of life for heart failure patients using a new innovative medical device that increases cardiac pumping. This new principle of treatment that improves the hearts natural movement will help heart failure patients with positive effects on quality of life, morbidity and mortality and also decrease the readmission rate for the patients.
Expected results and effects
A permanet active implantable product that improves the longitudinal movement of the mitral plane and therby increases cardiac output on heart failure patients. Our final product, Syntach Cardiac Support, is a permanent and active implant that can be inserted with minimal invasive technique and do not need cables through the skin. It is smaller and are therefore suitable for both men and women. The product and the method exposes the patient to lower risk than present products - This provides significant advantages for the product compared to present products.
Planned approach and implementation
In this step the development of the product will be finalized. Prototypes will in parallel be tested and verified in animal studies. User groups will be initiated to involve end users in the development. Computer modelling will be further developed to visualize the effect of the product. The project partners are Syntach, the company developing the product and owning the intellectual property rights; Lund University, where research on the scientific background for the product takes place and Region of Skåne where the end users are with clinicians and heart failure patients.